149 related articles for article (PubMed ID: 29676486)
1. Comments on the article: 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation'- Response to Pan et al.
Cheng Y; Chen Y; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Huang X
Br J Haematol; 2019 Mar; 184(5):882-883. PubMed ID: 29676486
[No Abstract] [Full Text] [Related]
2. Comments on the article 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation'.
Pan T; Qi J; Liu Y; Wu D; Han Y
Br J Haematol; 2019 Mar; 184(5):881-882. PubMed ID: 29676457
[No Abstract] [Full Text] [Related]
3. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
4. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
5. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
6. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
7. CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.
Martínez-Romera I; Galán-Gómez V; González-Martínez B; Guerra García P; San Román Pacheco S; Corral Sánchez D; Mozo Del Castillo Y; Bueno Sánchez D; Sisinni L; González Guerrero A; Castellano Dámaso S; Sánchez Zapardiel E; Ruz Caracuel B; Balas Pérez A; Pérez-Martínez A
Front Immunol; 2022; 13():960412. PubMed ID: 36003375
[TBL] [Abstract][Full Text] [Related]
8. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
10. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
Jin X; Cao Y; Wang L; Sun R; Cheng L; He X; Xiao X; Jiang Y; Li Q; Zhang H; Lu W; Lyu C; Jiang Y; Meng J; Zhao M
Leukemia; 2020 Mar; 34(3):909-913. PubMed ID: 31628429
[No Abstract] [Full Text] [Related]
11. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
Jia H; Wang Z; Wang Y; Liu Y; Dai H; Tong C; Guo Y; Guo B; Ti D; Han X; Yang Q; Wu Z; Han W
J Hematol Oncol; 2019 Jun; 12(1):57. PubMed ID: 31182121
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
[No Abstract] [Full Text] [Related]
14. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
15. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
Front Immunol; 2022; 13():965932. PubMed ID: 36225940
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cellular immunotherapy with CD19-specific T cells.
Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
20. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
